🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Dana B. Cardin

Vanderbilt University Medical Center

ORCID: 0000-0002-0269-9615
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors”.

First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4141
N/A
0.108DataRank · unranked
1 citations

Dana B. Cardin, F. Stephen Hodi, Patricia LoRusso, Taha Merghoub, Roberta Zappasodi +8 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789
N/A
0DataRank · unranked
53 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

Journal of Nuclear Medicine(2021)10.2967/jnumed.120.261594
N/A
0DataRank · unranked
30 citations

Joe Grudzinski, Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, Tiffany L. Hickman +9 more

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.363
N/A
0DataRank · unranked
1 citations

Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah +9 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563
N/A
0DataRank · unranked
0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4109
N/A
0DataRank · unranked
0 citations

Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad +13 more

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9065
N/A
0DataRank · unranked
10 citations

Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato, Primo N. Lara +12 more

Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4136
N/A
0DataRank · unranked
12 citations

Anup Kasi, Laith Abushahin, Dana B. Cardin, Heinz‐Josef Lenz, Farshid Dayyani +15 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176
N/A
0DataRank · unranked
0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1
N/A
0DataRank · unranked
0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3133
N/A
0DataRank · unranked
16 citations

Seong-Woo Bae, Jennifer G. Whisenant, Gregory D. Ayers, Quanhu Sheng, Todd E. Peterson +15 more

Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma

Clinical Colorectal Cancer(2022)10.1016/j.clcc.2022.03.003
N/A
0DataRank · unranked
12 citations

Jill Gilbert, Jennifer G. Whisenant, Gregory D. Ayers, Florencia G. Jalikis, Kimberly B. Dahlman +5 more